期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Topical use of tranexamic acid:Are there concerns for cytotoxicity?
1
作者 Ioannis Gkiatas Aristeidis-Panagiotis Kontokostopoulos +4 位作者 Spyridon E Tsirigkakis Ioannis Kostas-Agnantis Ioannis Gelalis anastasios korompilias Emilios Pakos 《World Journal of Orthopedics》 2022年第6期555-563,共9页
Tranexamic acid(TXA)has revolutionized modern blood management in orthopaedic surgery,especially in total joint arthroplasty,by significantly reducing blood loss and transfusion rates.It is an antifibrinolytic agent a... Tranexamic acid(TXA)has revolutionized modern blood management in orthopaedic surgery,especially in total joint arthroplasty,by significantly reducing blood loss and transfusion rates.It is an antifibrinolytic agent and a synthetic derivative of the amino acid lysine,which can inhibit the activation of plasminogen and the fibrin breakdown process.The administration of TXA can be intravenous(IV),topical,and oral.In patients where the IV administration is contraindicated,topical use is preferred.Topical administration of the drug theoretically increases concentration at the operative site with reduced systemic exposure,reduces cost,and gives the surgeon the control of the administration.According to recent studies,topical administration of TXA is not inferior compared to IV administration,in terms of safety and efficacy.However,there are concerns regarding the possible toxicity in the cartilage tissue with the topical use of TXA mainly in hemiarthroplasty operations of the hip,unilateral knee arthroplasties,total knee arthroplasties where the patella is not resurfaced,and other intraarticular procedures,like anterior cruciate ligament reconstruction.The purpose of the present review is to present all the recent updates on the use of TXA focusing on the toxicity on chondrocytes and the articular cartilage that may or may not be provoked by the topical use of TXA. 展开更多
关键词 Tranexamic acid Topical use CYTOTOXICITY Orthopaedic surgery
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部